TY - JOUR
T1 - Late relapses in acute myeloid leukemia
T2 - Analysis of characteristics and outcome
AU - Verma, Dushyant
AU - Kantarjian, Hagop
AU - Faderl, Stefan
AU - O'Brien, Susan
AU - Pierce, Sherry
AU - Vu, Khanh
AU - Freireich, Emil
AU - Keating, Michael
AU - Cortes, Jorge
AU - Ravandi, Farhad
PY - 2010/5
Y1 - 2010/5
N2 - Relapse after 5 years of complete remission (CR) is uncommon in acute myeloid leukemia (AML). Among 2347 patients seen between 1980 and 2008, 1366 achieved CR; 942 relapsed. Eleven (1.16 of all relapses) relapsed after a CR of>5 years. The median age was 66 years (range, 3779). Initial therapy was cytarabine plus anthracycline in six, amsacrine-based in three, and other in two. The median CR1 duration was 81 months (range, 60137). At relapse, the karyotype was different from the initial finding in five of eight (63) patients with available data. Treatment for relapse included cytarabine with anthracycline in eight, and other in three patients, with a second CR (CR2) achieved in four (36). The median CR2 duration was 1 month (range, 037), and median survival after relapse was 6.4 months (range, 139). Late relapses in AML are infrequent, with poor response to therapy. Karyotype at relapse is frequently different, raising the question of second AML versus relapse with the original clone.
AB - Relapse after 5 years of complete remission (CR) is uncommon in acute myeloid leukemia (AML). Among 2347 patients seen between 1980 and 2008, 1366 achieved CR; 942 relapsed. Eleven (1.16 of all relapses) relapsed after a CR of>5 years. The median age was 66 years (range, 3779). Initial therapy was cytarabine plus anthracycline in six, amsacrine-based in three, and other in two. The median CR1 duration was 81 months (range, 60137). At relapse, the karyotype was different from the initial finding in five of eight (63) patients with available data. Treatment for relapse included cytarabine with anthracycline in eight, and other in three patients, with a second CR (CR2) achieved in four (36). The median CR2 duration was 1 month (range, 037), and median survival after relapse was 6.4 months (range, 139). Late relapses in AML are infrequent, with poor response to therapy. Karyotype at relapse is frequently different, raising the question of second AML versus relapse with the original clone.
KW - AML
KW - Acute myeloid leukemia
KW - Late relapse
UR - http://www.scopus.com/inward/record.url?scp=77951864626&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951864626&partnerID=8YFLogxK
U2 - 10.3109/10428191003661852
DO - 10.3109/10428191003661852
M3 - Article
C2 - 20196624
AN - SCOPUS:77951864626
SN - 1042-8194
VL - 51
SP - 778
EP - 782
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5
ER -